Desipramine
| Clinical data | |
|---|---|
| Trade names | Norpramin, Pertofrane, others | 
| Other names | Desmethylimipramine; Norimipramine; EX-4355; G-35020; JB-8181; NSC-114901 | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682387 | 
| Routes of administration | Oral, intramuscular injection | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 60–70% | 
| Protein binding | 91% | 
| Metabolism | Liver (CYP2D6) | 
| Elimination half-life | 12–30 hours | 
| Excretion | Urine (70%), feces | 
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.037 | 
| Chemical and physical data | |
| Formula | C18H22N2 | 
| Molar mass | 266.388 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Desipramine, sold under the brand name Norpramin among others, is a tricyclic antidepressant (TCA) used in the treatment of depression. It acts as a relatively selective norepinephrine reuptake inhibitor, though it does also have other activities such as weak serotonin reuptake inhibitory, α1-blocking, antihistamine, and anticholinergic effects. The drug is not considered a first-line treatment for depression since the introduction of selective serotonin reuptake inhibitor (SSRI) antidepressants, which have fewer side effects and are safer in overdose.